NXTC
NextCure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.82
−0.26%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +30.8%
- EBIT
- +31.3%
- EPS
- +59.2%
- Free cash flow
- +31.8%
- Operating cash flow
- +31.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +43.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- +1.3%
- EBIT
- +3.6%
- Net income
- -0.3%
- EPS
- +17.7%
- Free cash flow
- -20.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026